help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2006-0152
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/6/2657    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hattersley, A. T.
Right arrow Articles by Pearson, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hattersley, A. T.
Right arrow Articles by Pearson, E. R.
Endocrinology Vol. 147, No. 6 2657-2663
Copyright © 2006 by The Endocrine Society

Minireview: Pharmacogenetics and Beyond: The Interaction of Therapeutic Response, ß-Cell Physiology, and Genetics in Diabetes

Andrew T. Hattersley and Ewan R. Pearson

Peninsula Medical School (A.T.H., E.R.P.), Exeter EX2 5DW, United Kingdom; and Ninewells Hospital and Medical School (E.R.P.), Dundee DD1 9SY, Scotland, United Kingdom

Address all correspondence and requests for reprints to: Dr. Andrew T. Hattersley, Peninsula Medical School, Barrack Road, Exeter EX2 5DW, United Kingdom. Email: a.t.hattersley{at}exeter.ac.uk.

Defining the molecular genetics of diabetes gives new insight into the underlying etiology and so should help improve treatment. The genetic etiology is now known for most patients with ß-cell monogenic diabetes, allowing genetic classification. We review how this genetic knowledge alters treatment. Patients with a glucose-sensing ß-cell defect due to glucokinase mutations have regulated, mild, fasting hyperglycemia. Oral hypoglycemic agents or low-dose insulin rarely improve glycemic control. Patients with hepatic nuclear factor-1{alpha} (HNF1{alpha}) mutations have progressive ß-cell deterioration and require treatment. HNF1{alpha} patients are 4 times more sensitive to sulfonylureas than matched type 2 diabetic patients. This is partly due to greater insulin secretion, reflecting the fact that the defect in HNF1{alpha} deficiency precedes the KATP channel where sulfonylureas act. HNF1ß is expressed in pancreatic stem cells before differentiation into endocrine or exocrine cells, so patients with HNF1ß mutations have reduced pancreatic development, resulting in early-onset diabetes and exocrine dysfunction. These patients usually rapidly require insulin and are not sensitive to sulfonylureas. Thirty-five to 50% of patients diagnosed with diabetes before 6 months have a mutation in Kir6.2. The mutated KATP channel in these patients does not close in response to increased ATP concentrations, but can be closed when sulfonylureas bind to the sulfonylurea receptor 1 subunit of the channel by an ATP-independent route. These patients are usually insulin dependent, but have excellent glycemic control on high-dose sulfonylureas tablets. In conclusion, the defining of molecular genetic etiology in monogenic diabetes has identified several specific ß-cell defects, and these are critical in determining the response to treatment.




This article has been cited by other articles:


Home page
DiabetesHome page
E. L. Edghill, S. E. Flanagan, A.-M. Patch, C. Boustred, A. Parrish, B. Shields, M. H. Shepherd, K. Hussain, R. R. Kapoor, M. Malecki, et al.
Insulin Mutation Screening in 1,044 Patients With Diabetes: Mutations in the INS Gene Are a Common Cause of Neonatal Diabetes but a Rare Cause of Diabetes Diagnosed in Childhood or Adulthood
Diabetes, April 1, 2008; 57(4): 1034 - 1042.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Polak, A. Dechaume, H. Cave, R. Nimri, H. Crosnier, V. Sulmont, M. de Kerdanet, R. Scharfmann, Y. Lebenthal, P. Froguel, et al.
Heterozygous Missense Mutations in the Insulin Gene Are Linked to Permanent Diabetes Appearing in the Neonatal Period or in Early Infancy: A Report From the French ND (Neonatal Diabetes) Study Group
Diabetes, April 1, 2008; 57(4): 1115 - 1119.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
K. L. Jones
Role of Obesity in Complicating and Confusing the Diagnosis and Treatment of Diabetes in Children
Pediatrics, February 1, 2008; 121(2): 361 - 368.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Stoy, E. L. Edghill, S. E. Flanagan, H. Ye, V. P. Paz, A. Pluzhnikov, J. E. Below, M. G. Hayes, N. J. Cox, G. M. Lipkind, et al.
Insulin gene mutations as a cause of permanent neonatal diabetes
PNAS, September 18, 2007; 104(38): 15040 - 15044.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
B. Liljestrom, T. Tuomi, B. Isomaa, L. Sarelin, K. Aktan-Collan, and H. Kaariainen
Adolescents at Risk for MODY3 Diabetes Prefer Genetic Testing Before Adulthood
Diabetes Care, June 1, 2007; 30(6): 1571 - 1573.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society